We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Agios Pharmaceuticals Inc | NASDAQ:AGIO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 34.58 | 34.55 | 37.03 | 4 | 09:00:26 |
From May 2021 to May 2024
By Colin Kellaher
Agios Pharmaceuticals Inc. Monday said it filed for U.S. Food and Drug Administration approval of mitapivat for the treatment of adults with pyruvate kinase, or PK, deficiency.
The Cambridge, Mass., biopharmaceutical company said there are currently no approved therapies for PK deficiency, a rare genetic disorder characterized by the premature destruction of red blood cells.
Agios said it is on track to file for European Union approval of mitapivat in mid-2021.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 21, 2021 07:37 ET (11:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Agios Pharmaceuticals Chart |
1 Month Agios Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
